IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.
Earnings for IO Biotech, Inc. (IOBT)
Earnings in 2023 (TTM): $-85,231,000
According to IO Biotech, Inc.'s latest financial reports the company's current earnings (TTM) are $-85,231,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of IO Biotech, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-85,231,000 | $-86,083,000 |
| 2022 | $-70,185,000 | $-71,458,000 |
| 2021 | $-67,811,000 | $-67,879,000 |
| 2020 | $-12,042,000 | $-12,068,000 |
| 2019 | $-10,743,000 | $-10,749,000 |